Geovax Labs Inc (GOVX)

$2.92

-0.1

(-3.31%)

Market is closed - opens 7 PM, 19 Jul 2024

Performance

  • $2.83
    $3.05
    $2.92
    downward going graph

    3.16%

    Downside

    Day's Volatility :7.29%

    Upside

    4.26%

    downward going graph
  • $1.09
    $10.24
    $2.92
    downward going graph

    62.67%

    Downside

    52 Weeks Volatility :89.36%

    Upside

    71.48%

    downward going graph

Returns

PeriodGeovax Labs IncSector (Health Care)Index (Russel 2000)
3 Months
98.68%
8.7%
0.0%
6 Months
-33.97%
8.0%
0.0%
1 Year
-65.29%
14.0%
0.0%
3 Years
-95.32%
17.0%
-18.2%

Highlights

Market Capitalization
7.5M
Book Value
$0.02
Earnings Per Share (EPS)
-14.46
PEG Ratio
0.0
Wall Street Target Price
72.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-115.22%
Return On Equity TTM
-242.41%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
81.5K
EBITDA
-28.3M
Diluted Eps TTM
-14.46
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-8.72
EPS Estimate Next Year
-1.76
EPS Estimate Current Quarter
-5.56
EPS Estimate Next Quarter
-5.82

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Geovax Labs Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 2365.75%

Current $2.92
Target $72.00

Technicals Summary

Sell

Neutral

Buy

Geovax Labs Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Geovax Labs Inc
Geovax Labs Inc
58.95%
-33.97%
-65.29%
-95.32%
-93.15%
Moderna, Inc.
Moderna, Inc.
-6.91%
25.22%
1.18%
-60.44%
769.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.48%
16.73%
49.42%
85.5%
258.18%
Novo Nordisk A/s
Novo Nordisk A/s
-3.82%
25.91%
69.01%
206.62%
460.98%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.51%
12.79%
36.04%
145.12%
174.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Geovax Labs Inc
Geovax Labs Inc
NA
NA
0.0
-8.72
-2.42
-1.15
NA
0.02
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.36
32.36
1.46
44.28
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.75
31.75
0.53
17.06
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Geovax Labs Inc
Geovax Labs Inc
Buy
$7.5M
-93.15%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
769.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$120.7B
258.18%
32.36
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
460.98%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.2B
174.23%
31.75
39.46%

Insights on Geovax Labs Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 69.0% return, outperforming this stock by 134.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 205.5% return, outperforming this stock by 300.7%

Institutional Holdings

  • Armistice Capital, LLC

    7.04%
  • BlackRock Inc

    1.09%
  • Vanguard Group Inc

    0.76%
  • Geode Capital Management, LLC

    0.44%
  • Tower Research Capital LLC

    0.18%
  • Wells Fargo & Co

    0.01%

Company Information

geovax labs, inc., (otcqb: govx) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our modified vaccinia ankara - virus-like particle (mva-vlp) vaccine platform. our development programs are focused on preventive vaccines against hiv, zika virus, hemorrhagic fever viruses (ebola, sudan, marburg, and lassa), and malaria, as well as therapeutic vaccines for chronic hepatitis b infections and cancers. our mva-vlp platform supports in vivo production of non-infectious vlps from the cells of the very person receiving the vaccine, mimicking a natural infection, and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. for more information, visit www.geovax.com.

Organization
Geovax Labs Inc
Employees
17
CEO
Mr. David Alan Dodd
Industry
Biotechnology

FAQs